Skip to main content
Naiyer Rizvi, MD, Oncology, New York, NY

Naiyer A Rizvi MD

Oncology•New York, NY

Thoracic Cancer

Professor of Medicine, Columbia University Medical Center

Join to view full profile

  • 1275 York AveNew York, NY 10065

  • Phone+1 646-227-3813

  • Fax+1 212-305-3035

Dr. Rizvi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Rizvi's full profileAlready have an account?

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1995
  • University of Manitoba
    University of ManitobaClass of 1987

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2002 - 2027
  • DC State Medical License
    DC State Medical License 1995 - 2002
  • VA State Medical License
    VA State Medical License 1996 - 2002

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2016-2017
  • CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2016-2017
  • Top Doctors: New York Metro Area Castle Connolly, 2008-2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)  
    Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences

Lectures

  • Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy ... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Lung Cancer. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1) 
    2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

  • First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
    First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung CancerNovember 13th, 2025
  • Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
    Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung CancerNovember 7th, 2025
  • As Biotech Debates Vaccine Mandates, One CEO Tries to Convince the 3% That Got Away
    As Biotech Debates Vaccine Mandates, One CEO Tries to Convince the 3% That Got AwayAugust 11th, 2021

Grant Support

  • Early Clinical Trials Of New Anti-Cancer Agents With Phase 1 EmphasisNational Cancer Institute2008
  • Phase I Clinical Trials Of Novel AgentsNational Cancer Institute2006–2007
  • Foreign Accrual For 5u10ca069856 2006 Load Phase I U01 Rizvi MskiNational Cancer Institute2006
  • Correlation Of EGFR Mutations And Response To GefitinibNational Cancer Institute2005–2006
  • Pv701 Safety/Efficacy In Advanced/Recurrent Solid TumorsNational Center For Research Resources2000

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Naiyer Rizvi, Dr. Naiyer Rizvi, MD, Dr. N Rizvi, Dr. Naiyer A Rizvi